Company Update (NYSE MKT:ISR): Gynecologic Cancers Successfully Treated Using IsoRay’s Cesium-131 will be Presented by Dr. Jonathan Feddock Saturday Night

IsoRay Inc. (NYSE MKT: ISR) (, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a dinner presentation on March 28 by Dr. Jonathan Feddock describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131. IsoRay will have booth #516 at the 2015 Annual Meeting of the Society of Gynecologic Oncology (SGO). The annual meeting will take place March 28-31, 2015 at the Chicago Hilton in Chicago, Illinois.

According to IsoRay CEO Dwight Babcock, “With the recently published and peer-reviewed results for gynecologic cancer, we are seeing a growing level of interest by gynecologic oncologists due to the significant results being achieved using Cesium-131. Cesium-131’s reported success in treating primary as well as recurrent gynecologic cancers that have not responded to other treatments continues to get the attention of physicians who need new treatment options.”

IsoRay is very pleased to have Dr. Feddock, an industry leader who practices at University of Kentucky HealthCare, discuss the success, methods and new approaches being implemented in brachytherapy.

Mr. Babcock added, “The medical community is continually being shown the unique ability of IsoRay’ s Cesium-131 (Cs-131) seeds, seed sutured, seeded mesh and GliaSite® system for the treatment of a wide array of cancers throughout the body. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. We are extremely excited that published studies, posters and abstracts continue to be released showing positive results realized in treating metastasized brain cancers, gynecological cancers, lung cancer and prostate cancer using Cs-131 or GliaSite®.”

IsoRay’s Cesium-131 sutured seeds, stranded mesh and the GliaSite® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue as well as critical structures compared to other alternative treatments. IsoRay’s cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers.(Original Source)

Shares of IsoRay Inc opened today at $1.69 and are currently trading down at $1.67. ISR has a 1-year high of $3.47 and a 1-year low of $1.22. The stock's 50-day moving average is $1.49 and it's 200-day moving average is $1.62.

On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, which implies an upside of 195.9% from current levels, In a report issued on February 18. According to, Kolbert has a total average return of 12.3%, a 47.9% success rate, and is ranked #233 out of 3546 analysts.

IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts